With 120 home-based patients to be recruited into the trial and 100 hospital-based patients already recruited into the trial, the ease of use of Phlexglobal’s eTMF technology and support services were key factors in Synairgen’s decision.
Phlexglobal’s advanced eTMF includes built-in best practices to improve TMF health, including embedded quality review, event management, wizard-driven completeness, intelligent placeholders, and more. This singular focus on customer-driven innovation frees life sciences companies to put more resources behind their primary goal: bringing safe, life-improving new therapies to patients faster, and with less risk.
In addition, PhlexTMF features the industry’s only AI-assisted TMF indexing technology, which reduces document processing time significantly. Leveraging pre-trained neural networks of sophisticated algorithms to identify and extract attribute values from TMF documents, the feature allows study teams to focus on critical tasks rather than on repetitive and time-consuming manual effort.
“Discussions with multiple people at Phlexglobal gave us the confidence that they were the right match for our company, our study, and our very tight timeline,” said Jody Brookes, Head of Clinical Operations at Synairgen. “Like us, they have a tremendous culture of innovation, and a spirit of genuine collaboration that has made a real difference in the project. Given the speed and quality of the service, going with Phlexglobal was absolutely the right decision.”
COVID-19 Support: Phlexglobal Resources to Fast Track Trials and Ensure Business Continuity
If you have any questions regarding the impact of COVID-19 from a clinical or regulatory standpoint, you can submit them to Phlexglobal and the will provide answers within one business day. If you need support for your research, Contact Phlexglobal today to receive COVID-19 study help tomorrow.
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. For more information about Synairgen, please see www.synairgen.com.
About the Synairgen COVID-19 Study
Synairgen’s clinical trial in COVID-19 patients (SG016) is a randomised, double-blind, placebo-controlled trial. The 220-patient trial comprises 100 patients initiated in hospital and 120 patients to be initiated in the home setting. The patients participating in the hospital setting, which completed recruitment in May, have been recruited across a number of NHS trusts and the trial has been adopted by the NIHR Respiratory Translational Research Collaboration. Synairgen announced positive preliminary results from the hospital setting on 20 July 2020 (https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf).